2022
Sustained virological response after treatment with direct antiviral agents in individuals with HIV and hepatitis C co‐infection
Lodi S, Klein M, Rauch A, Epstein R, Wittkop L, Logan R, Rentsch C, Justice A, Touloumi G, Berenguer J, Jarrin I, Egger M, Puoti M, Monforte A, Gill J, Ceron D, van Sighem A, Linas B, van der Valk M, Hernán M, Collaboration H. Sustained virological response after treatment with direct antiviral agents in individuals with HIV and hepatitis C co‐infection. Journal Of The International AIDS Society 2022, 25: e26048. PMID: 36562643, PMCID: PMC9784654, DOI: 10.1002/jia2.26048.Peer-Reviewed Original ResearchConceptsSustained virological responseHCV RNA testingDAA treatmentSVR ratesVirological responseProbability of SVRHepatitis C virus (HCV) cureRoutine HCV RNA testingActing antiviral (DAA) treatmentDAA treatment initiationCD4 cell countDirect antiviral agentsPresence of cirrhosisHCV RNA testEnd of treatmentClinical strataDAA recipientsHIV-HCVSVR assessmentSVR statusHIV acquisitionClinical characteristicsAntiviral treatmentTreatment initiationHCV genotypesAntiviral Strategies Against SARS-CoV-2: A Systems Biology Approach
Prates ET, Garvin MR, Jones P, Miller JI, Sullivan KA, Cliff A, Gazolla JGFM, Shah MB, Walker AM, Lane M, Rentsch CT, Justice A, Pavicic M, Romero J, Jacobson D. Antiviral Strategies Against SARS-CoV-2: A Systems Biology Approach. Methods In Molecular Biology 2022, 2452: 317-351. PMID: 35554915, DOI: 10.1007/978-1-0716-2111-0_19.ChaptersMeSH KeywordsAntiviral AgentsArtificial IntelligenceCOVID-19 Drug TreatmentHumansPandemicsSARS-CoV-2Systems BiologyConceptsSystems biology approachBiology approachHigh-performance computingArtificial intelligence methodologiesDiversity of informationIntelligence methodologiesStructural proteomicsSystem-level infrastructureMultiomics integrationCore frameworkViral pathogenesisAntiviral strategiesWealth of informationUnprecedented accessPathogensComputingComputational protocolPathogen detectionInformationProteomicsAdaptation analysisDevelopment of vaccinesProtocolInfrastructureNetwork
2021
Protease inhibitor-based direct-acting antivirals are associated with increased risk of aminotransferase elevations but not hepatic dysfunction or decompensation
Torgersen J, Newcomb CW, Carbonari DM, Rentsch CT, Park LS, Mezochow A, Mehta RL, Buchwalder L, Tate JP, Bräu N, Bhattacharya D, Lim JK, Taddei TH, Justice AC, Lo Re V. Protease inhibitor-based direct-acting antivirals are associated with increased risk of aminotransferase elevations but not hepatic dysfunction or decompensation. Journal Of Hepatology 2021, 75: 1312-1322. PMID: 34333102, PMCID: PMC8604762, DOI: 10.1016/j.jhep.2021.07.021.Peer-Reviewed Original ResearchConceptsSevere hepatic dysfunctionBaseline FIB-4Acute liver injuryHepatic dysfunctionInhibitor-based treatmentHepatic decompensationFIB-4Liver injuryHigh riskDAA therapyHazard ratioAdvanced liver fibrosis/cirrhosisRisk of ALIProtease inhibitor-based regimensProtease inhibitor-based treatmentLiver fibrosis/cirrhosisInhibitor-based regimensHepatitis C infectionSevere liver dysfunctionFibrosis/cirrhosisInhibitor-based therapyAminotransferase elevationChronic HCVALT elevationC infectionCOVID-19 Evidence Accelerator: A parallel analysis to describe the use of Hydroxychloroquine with or without Azithromycin among hospitalized COVID-19 patients
Stewart M, Rodriguez-Watson C, Albayrak A, Asubonteng J, Belli A, Brown T, Cho K, Das R, Eldridge E, Gatto N, Gelman A, Gerlovin H, Goldberg SL, Hansen E, Hirsch J, Ho YL, Ip A, Izano M, Jones J, Justice AC, Klesh R, Kuranz S, Lam C, Mao Q, Mataraso S, Mera R, Posner DC, Rassen JA, Siefkas A, Schrag A, Tourassi G, Weckstein A, Wolf F, Bhat A, Winckler S, Sigal EV, Allen J. COVID-19 Evidence Accelerator: A parallel analysis to describe the use of Hydroxychloroquine with or without Azithromycin among hospitalized COVID-19 patients. PLOS ONE 2021, 16: e0248128. PMID: 33730088, PMCID: PMC7968637, DOI: 10.1371/journal.pone.0248128.Peer-Reviewed Original ResearchConceptsHospitalized COVID-19 patientsCOVID-19 patientsUse of hydroxychloroquineElectronic health recordsAdverse eventsTreatment groupsCOVID-19Administration of hydroxychloroquineReagan-Udall FoundationProportional hazards modelHealth systems researchHospitalized patientsElevated riskPropensity score methodsHazards modelHydroxychloroquinePatientsSignificant global threatPharmaceutical interventionsAzithromycinHealth recordsMortalityCOVID-19 pandemicCancer researchTreatment
2020
Excess Weight Gain After Cure of Hepatitis C Infection with Direct-Acting Antivirals
Do A, Esserman DA, Krishnan S, Lim JK, Taddei TH, Hauser RG, Tate JP, Re VL, Justice AC. Excess Weight Gain After Cure of Hepatitis C Infection with Direct-Acting Antivirals. Journal Of General Internal Medicine 2020, 35: 2025-2034. PMID: 32342483, PMCID: PMC7352003, DOI: 10.1007/s11606-020-05782-6.Peer-Reviewed Original ResearchMeSH KeywordsAntiviral AgentsHepacivirusHepatitis CHepatitis C, ChronicHumansProspective StudiesTreatment OutcomeWeight GainConceptsDAA treatmentExcess weight gainTreatment initiationWeight gainChronic hepatitis C virus (HCV) infectionHigh FIB-4 scoreHepatitis C virus infectionC virus infectionFIB-4 scoreHepatitis C infectionDirect acting antiviralsLiver disease progressionMultiple logistic regressionConclusionWeight gainDAA therapySVR achievementC infectionBaseline weightProspective studyExcess weightDisease progressionVirus infectionHigh riskPatientsBirth cohort
2019
Regional and Rural-Urban Differences in the Use of Direct-acting Antiviral Agents for Hepatitis C Virus
Njei B, Esserman D, Krishnan S, Ohl M, Tate JP, Hauser RG, Taddei T, Lim J, Justice AC. Regional and Rural-Urban Differences in the Use of Direct-acting Antiviral Agents for Hepatitis C Virus. Medical Care 2019, 57: 279-285. PMID: 30807449, PMCID: PMC6436819, DOI: 10.1097/mlr.0000000000001071.Peer-Reviewed Original ResearchConceptsDirect-acting antiviral agentsHepatitis C virus infectionVeterans Affairs Healthcare SystemRural-Urban Commuting Area codesCurative HCV treatmentRural-urban designationC virus infectionElectronic health record dataHepatitis C virusPrior treatment experienceLower odds ratioHealth record dataZone improvement plan codeEligible patientsHCV treatmentAntiretroviral medicationsRural-urban residenceLiver diseaseUnadjusted analysesC virusRural-urban differencesOdds ratioMultivariable modelLower incidenceObservational study
2018
Provider verification of electronic health record receipt and nonreceipt of direct-acting antivirals for the treatment of hepatitis C virus infection
Rentsch CT, Cartwright EJ, Gandhi NR, Brown ST, Rodriguez-Barradas MC, Goetz MB, Marconi VC, Gibert CL, Re VL, Fiellin DA, Justice AC, Tate JP. Provider verification of electronic health record receipt and nonreceipt of direct-acting antivirals for the treatment of hepatitis C virus infection. Annals Of Epidemiology 2018, 28: 808-811. PMID: 30195616, PMCID: PMC6318448, DOI: 10.1016/j.annepidem.2018.08.007.Peer-Reviewed Original ResearchConceptsHepatitis C virus infectionCorporate Data WarehouseChronic HCV infectionC virus infectionPositive predictive valuePredictive valueHCV infectionHCV treatmentVirus infectionVeterans Health Administration Corporate Data WarehouseChronic hepatitis C virus (HCV) infectionStudy periodModern treatment eraRetrospective cohort studyElectronic health record dataPharmacy fill recordsHealth record dataNegative predictive valueElectronic health recordsAntiviral regimenHCV therapyTreatment eraChart reviewCohort studyAntiviral treatment
2016
HIV, Aging, and Viral Coinfections: Taking the Long View
Taddei TH, Re V, Justice AC. HIV, Aging, and Viral Coinfections: Taking the Long View. Current HIV/AIDS Reports 2016, 13: 269-278. PMID: 27614654, DOI: 10.1007/s11904-016-0327-7.Books
2014
Virologic response and haematologic toxicity of boceprevir‐ and telaprevir‐containing regimens in actual clinical settings
Butt AA, Yan P, Shaikh OS, Freiberg MS, Re V, Justice AC, Sherman KE, Team T. Virologic response and haematologic toxicity of boceprevir‐ and telaprevir‐containing regimens in actual clinical settings. Journal Of Viral Hepatitis 2014, 22: 691-700. PMID: 25524834, PMCID: PMC5020421, DOI: 10.1111/jvh.12375.Peer-Reviewed Original ResearchConceptsSustained virologic responsePEG/RBVHaematologic toxicityActual clinical settingsSVR ratesVirologic responseClinical settingHaematologic adverse eventsHCV Infected VeteransInterferon/ribavirinHCV genotype 1HCV RNA valuesPivotal clinical trialsHepatitis C virusBaseline cirrhosisHIV coinfectionPrimary endpointTreatment-naïveAdverse eventsC virusClinical trialsGenotype 1Genotype 1aSevere toxicityBoceprevir
2011
A Comparison of Treatment Eligibility for Hepatitis C Virus in HCV-Monoinfected Versus HCV/HIV-Coinfected Persons in Electronically Retrieved Cohort of HCV-Infected Veterans
Butt AA, McGinnis K, Skanderson M, Justice AC. A Comparison of Treatment Eligibility for Hepatitis C Virus in HCV-Monoinfected Versus HCV/HIV-Coinfected Persons in Electronically Retrieved Cohort of HCV-Infected Veterans. AIDS Research And Human Retroviruses 2011, 27: 973-979. PMID: 21338329, PMCID: PMC3719436, DOI: 10.1089/aid.2011.0004.Peer-Reviewed Original ResearchConceptsChronic obstructive pulmonary diseaseHepatitis C virusDecompensated liver diseaseHCV-HIVTreatment eligibilityC virusCohort of HCVVA National Patient Care DatabaseNational Patient Care DatabasePharmacy Benefits Management databaseHCV treatment eligibilityHCV-HIV coinfectionRecent alcohol abuseHCV/HIVCurrent treatment guidelinesProportion of patientsObstructive pulmonary diseaseCoronary artery diseasePatient Care DatabaseActual clinical settingsCoinfected PersonsAggressive managementCommon contraindicationsPharmacy recordsRenal failure
2009
Hepatitis C treatment completion rates in routine clinical care
Butt AA, McGinnis KA, Skanderson M, Justice AC. Hepatitis C treatment completion rates in routine clinical care. Liver International 2009, 30: 240-250. PMID: 19889081, PMCID: PMC3132089, DOI: 10.1111/j.1478-3231.2009.02156.x.Peer-Reviewed Original ResearchConceptsPre-treatment anemiaTreatment completion ratesVA National Patient Care DatabaseHuman immunodeficiency virus (HIV) coinfectionNational Patient Care DatabasePharmacy Benefits Management databaseHepatitis C virus infectionCompletion ratesHigher comorbidity countC virus infectionImmunodeficiency virus coinfectionCoronary artery diseasePatient Care DatabaseRoutine clinical careClinical practice settingTreatment sitesInitiate therapyInterferon useComorbidity countPharmacy recordsStandard interferonArtery diseaseVirus coinfectionMultivariable analysisCare databaseDo Benefits of Earlier Antiretroviral Treatment Initiation Outweigh Harms for Individuals at Risk for Poor Adherence?
Braithwaite RS, Roberts MS, Goetz MB, Gibert CL, Rodriguez-Barradas MC, Nucifora K, Justice AC. Do Benefits of Earlier Antiretroviral Treatment Initiation Outweigh Harms for Individuals at Risk for Poor Adherence? Clinical Infectious Diseases 2009, 48: 822-826. PMID: 19210173, PMCID: PMC3032571, DOI: 10.1086/596768.Peer-Reviewed Original Research
2006
Rate and predictors of treatment prescription for hepatitis C
Butt AA, Justice AC, Skanderson M, Rigsby MO, Good CB, Kwoh CK. Rate and predictors of treatment prescription for hepatitis C. Gut 2006, 56: 385. PMID: 17005764, PMCID: PMC1856823, DOI: 10.1136/gut.2006.099150.Peer-Reviewed Original ResearchConceptsHepatitis C virusNational Patient Care DatabaseTreatment prescriptionPrescription ratesAlcohol abuseVeterans Affairs National Patient Care DatabaseDiagnosis of HCVPharmacy Benefits Management databaseMultivariate logistic regression modelHepatitis B infectionCoronary artery diseasePatient Care DatabasePsychiatric comorbid conditionsNon-white raceLogistic regression analysisPredictors of treatmentAlcohol use diagnosisLogistic regression modelsB infectionComorbid illnessesHepatitis CArtery diseaseLiver cirrhosisComorbid conditionsHispanic race
2003
Testing, Referral, and Treatment Patterns for Hepatitis C Virus Coinfection in a Cohort of Veterans with Human Immunodeficiency Virus Infection
Fultz SL, Justice AC, Butt AA, Rabeneck L, Weissman S, Rodriguez-Barradas M, Team V. Testing, Referral, and Treatment Patterns for Hepatitis C Virus Coinfection in a Cohort of Veterans with Human Immunodeficiency Virus Infection. Clinical Infectious Diseases 2003, 36: 1039-1046. PMID: 12684917, DOI: 10.1086/374049.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAlcohol DrinkingAntiviral AgentsCarcinoma, HepatocellularFemaleHepacivirusHepatitis CHIVHIV InfectionsHumansMaleMiddle AgedConceptsAlcohol consumptionHepatitis CHuman immunodeficiency virus-positive patientsHepatitis C virus coinfectionHuman immunodeficiency virus (HIV) infectionImmunodeficiency virus-positive patientsC virus coinfectionUnderwent liver biopsyHepatitis C therapyImmunodeficiency virus infectionVirus-positive patientsHepatitis C treatmentTreatment of patientsCohort of veteransVeterans Affairs electronic medical recordsHepatitis C virusCurrent alcohol consumptionHealth care providersElectronic medical recordsC therapyCohort studyLiver biopsyTreatment patternsVirus coinfectionPsychiatric comorbidity